A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
For people in Pike County, deadly cancer is as much a part of their landscape as the Portsmouth Gaseous Diffusion Plant ...
The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...
Sharda Sinha, popularly known as 'Bihar Kokila' and known for her songs in Bhojpuri, Maithili, and Hindi languages, succumbed ...
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback